Grifols vs BeOne Medicines
GRFS and ONC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GRFS and ONC compare
BeOne Medicines grew revenue faster over the last twelve months (32.9% versus 4.3% for Grifols).
BeOne Medicines keeps more of each dollar of sales as profit, with a net margin of 13.9% compared with 5.3% at Grifols.
BeOne Medicines scores higher on the StockData Score (14 against 9 for Grifols), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GRFS | ONC |
|---|---|---|
| Size and price | ||
| Market cap | – | $616B |
| Share price | $8.69 | $416.54 |
| Change, 1 year | 0.00% | 10.4% |
| Change, 5 years | −26.9% | 14.3% |
| Beta (5Y) | 0.89 | 1.05 |
| Employees | 1,613 | 12K |
| StockData Score | ||
| Total score | 9 | 14 (better) |
| Valuation score | 0 | 0 |
| Growth score | 2 | 4 (better) |
| Performance score | 4 | 4 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 694× |
| P/S | – | 93.2× |
| P/B | – | 106× |
| EV/EBITDA | – | 450× |
| P/FCF | – | 425× |
| FCF yield | – | 0.24% |
| Fair value | – | $20.47 |
| Margin of safety | – | −1935% |
| Growth | ||
| Revenue growth (TTM) | 4.3% | 32.9% (better) |
| Revenue growth, 5Y average | 7.1% | 76.8% (better) |
| Net income growth (TTM) | 156% | 1236% (better) |
| EPS growth (TTM) | 157% | 1900% (better) |
| EPS growth, 5Y average | −8.1% | – |
| Profitability | ||
| Gross margin | 38.0% | 89.4% (better) |
| Operating margin | 16.5% | 17.8% (better) |
| Net margin | 5.3% | 13.9% (better) |
| FCF margin | 10.4% | 21.9% (better) |
| Return on equity | 7.2% | 18.4% (better) |
| Return on invested capital | 14.6% | 88.9% (better) |
| Financial health | ||
| Debt / equity | 0.41 | 0.21 (better) |
| Net debt / EBITDA | 0.79 (better) | −3.37 |
| Interest coverage | 2.0× | 8.3× (better) |
| Current ratio | 2.51 | 3.55 (better) |
| Altman Z-score | – | 91.79 |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Payout ratio | 31.8% | – |
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 20.8% | 2.4% |
| Held by insiders | 0.00% | 14.2% |
| Insider net buying, 12 months | – | −$384M |
Go deeper
- GRFS stock overview
- GRFS income statement
- GRFS valuation and score
- ONC stock overview
- ONC income statement
- ONC valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.